Opus Genetics FY2024 EPS Forecast Reduced by HC Wainwright

Opus Genetics, Inc. (NASDAQ:IRD) – Equities research analysts at HC Wainwright lowered their FY2024 EPS estimates for Opus Genetics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now expects that the company will earn ($1.22) per share for the year, down from their previous estimate of ($1.11). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.23) EPS.

Opus Genetics (NASDAQ:IRD) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.01. The company had revenue of $3.87 million during the quarter, compared to analysts’ expectations of $1.17 million. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%.

Opus Genetics Price Performance

Shares of NASDAQ IRD opened at $1.06 on Friday. Opus Genetics has a 1-year low of $0.97 and a 1-year high of $3.40. The firm has a market cap of $33.46 million, a P/E ratio of -0.97 and a beta of 0.22.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.